The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
Official Title: A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects With Tenosynovial Giant Cell Tumor
Study ID: NCT04938180
Brief Summary: The purpose of this Phase 2, open-label, multiple-dose, dose-escalation study is to evaluate intravenous AMB-05X in the treatment of subjects with TGCT.
Detailed Description: AMB-05X drug substance is a human monoclonal antibody against the colony-stimulating factor 1 receptor (CSF1R).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
AmMax Bio Clinical Site, Budapest, , Hungary
AmMax Bio Clinical Site, Warsaw, , Poland
AmMax Bio Clinical Site, Dnipro, , Ukraine
AmMax Bio Clinical Site, Kharkiv, , Ukraine
AmMax Bio Clinical Site, Kyiv, , Ukraine
Name: Dorothy Nguyen, MD
Affiliation: AmMax Bio, Inc.
Role: STUDY_CHAIR